Medivation, Inc. (MDVN) is on the rise during Monday's after-hours trading following news that its investigational drug Dimebon significantly improved cognitive function in patients with mild-to-moderate Huntington's disease.
At 4:32 pm ET the stock is trading at $14.50 up $2.39 from Monday's close.
With the advance, the stock stands to open having halted a recent downtrend and at its highest level in nearly a month.
For comments and feedback: editorial@rttnews.com